Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 120

1.

Interpreting results from oncology clinical trials: a comparison of denosumab to zoledronic acid for the prevention of skeletal-related events in cancer patients.

Dranitsaris G, Hatzimichael E.

Support Care Cancer. 2012 Jul;20(7):1353-60. doi: 10.1007/s00520-012-1461-4. Epub 2012 Apr 27. Review.

PMID:
22539050
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.

Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

J Manag Care Pharm. 2011 Oct;17(8):621-43.

PMID:
21942303
[PubMed - indexed for MEDLINE]
Free Article
3.

Bisphosphonates and other bone agents for breast cancer.

Wong MH, Stockler MR, Pavlakis N.

Cochrane Database Syst Rev. 2012 Feb 15;2:CD003474. doi: 10.1002/14651858.CD003474.pub3. Review.

PMID:
22336790
[PubMed - indexed for MEDLINE]
4.

Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.

Stopeck A, Rader M, Henry D, Danese M, Halperin M, Cong Z, Qian Y, Dansey R, Chung K.

J Med Econ. 2012;15(4):712-23. doi: 10.3111/13696998.2012.675380. Epub 2012 Mar 27.

PMID:
22409231
[PubMed - indexed for MEDLINE]
5.

Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials.

Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, Richardson GE, Siena S, Maroto P, Clemens M, Bilynskyy B, Charu V, Beuzeboc P, Rader M, Viniegra M, Saad F, Ke C, Braun A, Jun S.

Eur J Cancer. 2012 Nov;48(16):3082-92. doi: 10.1016/j.ejca.2012.08.002. Epub 2012 Sep 10.

PMID:
22975218
[PubMed - indexed for MEDLINE]
6.

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.

Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, de Boer RH, Lichinitser M, Fujiwara Y, Yardley DA, Viniegra M, Fan M, Jiang Q, Dansey R, Jun S, Braun A.

J Clin Oncol. 2010 Dec 10;28(35):5132-9. doi: 10.1200/JCO.2010.29.7101. Epub 2010 Nov 8.

PMID:
21060033
[PubMed - indexed for MEDLINE]
Free Article
7.

Skeletal-related events in metastatic prostate cancer and the number needed to treat: a critical consideration.

Schmitz-Dräger BJ, Weiss C, Ebert T, Dörsam J, Bismarck E.

Urol Int. 2013;90(3):329-33. doi: 10.1159/000346387. Epub 2013 Feb 9.

PMID:
23407093
[PubMed - indexed for MEDLINE]
8.

Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.

Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K.

Ann Oncol. 2012 Dec;23(12):3045-51. doi: 10.1093/annonc/mds175. Epub 2012 Jul 31.

PMID:
22851406
[PubMed - indexed for MEDLINE]
Free Article
9.

Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.

Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

Clin Breast Cancer. 2012 Aug;12(4):247-58. doi: 10.1016/j.clbc.2012.04.001. Epub 2012 Jun 12.

PMID:
22694824
[PubMed - indexed for MEDLINE]
10.

Cost-effectiveness of denosumab versus zoledronic acid in the management of skeletal metastases secondary to breast cancer.

Snedecor SJ, Carter JA, Kaura S, Botteman MF.

Clin Ther. 2012 Jun;34(6):1334-49. doi: 10.1016/j.clinthera.2012.04.008. Epub 2012 May 11.

PMID:
22578308
[PubMed - indexed for MEDLINE]
11.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C.

Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.

PMID:
21353695
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.

Henry D, Vadhan-Raj S, Hirsh V, von Moos R, Hungria V, Costa L, Woll PJ, Scagliotti G, Smith G, Feng A, Jun S, Dansey R, Yeh H.

Support Care Cancer. 2014 Mar;22(3):679-87. doi: 10.1007/s00520-013-2022-1. Epub 2013 Oct 26.

PMID:
24162260
[PubMed - indexed for MEDLINE]
13.

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a cost-effectiveness analysis.

Snedecor SJ, Carter JA, Kaura S, Botteman MF.

J Med Econ. 2013;16(1):19-29. doi: 10.3111/13696998.2012.719054. Epub 2012 Sep 5.

PMID:
22870908
[PubMed - indexed for MEDLINE]
14.

Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.

Ford J, Cummins E, Sharma P, Elders A, Stewart F, Johnston R, Royle P, Jones R, Mulatero C, Todd R, Mowatt G.

Health Technol Assess. 2013 Jul;17(29):1-386. doi: 10.3310/hta17290. Review.

PMID:
23870108
[PubMed - indexed for MEDLINE]
Free Article
15.

Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis.

Peddi P, Lopez-Olivo MA, Pratt GF, Suarez-Almazor ME.

Cancer Treat Rev. 2013 Feb;39(1):97-104. doi: 10.1016/j.ctrv.2012.07.002. Epub 2012 Aug 13. Review.

PMID:
22898302
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.

Sun L, Yu S.

Am J Clin Oncol. 2013 Aug;36(4):399-403. doi: 10.1097/COC.0b013e31824be20e. Review.

PMID:
22772430
[PubMed - indexed for MEDLINE]
17.

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H.

J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22.

PMID:
21343556
[PubMed - indexed for MEDLINE]
Free Article
18.

Zoledronic acid: a pharmacoeconomic review of its use in the management of bone metastases.

McKeage K, Plosker GL.

Pharmacoeconomics. 2008;26(3):251-68. Review.

PMID:
18282018
[PubMed - indexed for MEDLINE]
19.

Pharmacoeconomics of bisphosphonates for skeletal-related event prevention in metastatic non-breast solid tumours.

Carter JA, Joshi AD, Kaura S, Botteman MF.

Pharmacoeconomics. 2012 May;30(5):373-86. doi: 10.2165/11631390-000000000-00000. Review.

PMID:
22500986
[PubMed - indexed for MEDLINE]
20.

Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid.

von Moos R, Body JJ, Egerdie B, Stopeck A, Brown JE, Damyanov D, Fallowfield LJ, Marx G, Cleeland CS, Patrick DL, Palazzo FG, Qian Y, Braun A, Chung K.

Support Care Cancer. 2013 Dec;21(12):3497-507. doi: 10.1007/s00520-013-1932-2. Epub 2013 Aug 22.

PMID:
23975226
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk